Mathieu Rouanne

List of Publications by Year
in descending order

54	4,283	331259 21	189595 50
papers	citations	h-index	g-index

57	57	57	5334
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e1-12.e11.	0.8	6
2	Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals. European Journal of Cancer, 2022, 162, 130-132.	1.3	0
3	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	11
4	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 2021, 79, 82-104.	0.9	1,152
5	PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World Journal of Urology, 2021, 39, 1345-1355.	1.2	13
6	â€œFuture role of [18F]-FDG PET/CT in patients with bladder cancer in the new era of neoadjuvant immunotherapy?â€• Urologic Oncology: Seminars and Original Investigations, 2021, 39, 139-141.	0.8	0
7	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced nonâ€“small cell lung cancer treated with immunotherapy. European Journal of Cancer, 2021, 145, 221-229.	1.3	42
8	CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer. European Journal of Cancer, 2021, 151, 245-248.	1.3	14
9	Utility of Routine Preoperative 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. Letter.. Journal of Urology, 2021, 206, 169-170.	0.2	0
10	Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature Reviews Cancer, 2021, 21, 701-717.	12.8	150
11	Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy. Asian Journal of Andrology, 2021, 23, 370.	0.8	1
12	Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy. Asian Journal of Andrology, 2021, 23, 520.	0.8	2
13	Immunodynamics of explanted human tumors for immunoâ€•oncology. EMBO Molecular Medicine, 2021, 13, e12850.	3.3	9
14	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. European Urology Oncology, 2020, 3, 131-144.	2.6	61
15	Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer. Scientific Reports, 2020, 10, 16145.	1.6	5
16	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. European Urology Oncology, 2020, 3, 728-738.	2.6	61
17	Pegylated Engineered IL2 plus Antiâ€“PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. Cancer Discovery, 2020, 10, 1097-1099.	7.7	7
18	The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. Frontiers in Oncology, 2020, 10, 565086.	1.3	20

#	Article	IF	Citations
19	Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies. , 2020, 8, e000579.		17
20	European Association of Urology Guidelines on Primary Urethral Carcinomaâ€”2020 Update. European Urology Oncology, 2020, 3, 424-432.	2.6	28
21	c-Met activation leads to the establishment of a TGFÎ²-receptor regulatory network in bladder cancer progression. Nature Communications, 2019, 10, 4349.	5.8	44
22	Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) nonâ€“muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. PLoS ONE, 2019, 14, e0211721.	1.1	17
23	Comment on: Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1212-1213.	3.3	2
24	Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. European Radiology, 2019, 29, 4286-4293.	2.3	48
25	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. European Urology, 2019, 75, 423-432.	0.9	205
26	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. European Journal of Cancer, 2019, 108, 111-119.	1.3	16
27	Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial). Prostate, 2019, 79, 272-280.	1.2	9
28	Reply to Pontus Eriksson and Gottfrid SjÃ¶dahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423â€“32. European Urology, 2019, 75, e108-e109.	0.9	4
29	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. Hormones and Cancer, 2019, 10, 36-44.	4.9	23
30	PARP inhibition enhances tumor cellâ€“intrinsic immunity in ERCC1-deficient nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228.	3.9	222
31	Re: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology, 2018, 199, 854-856.	0.2	0
32	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World Journal of Urology, 2018, 36, 1727-1740.	1.2	75
33	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Urology, 2017, 71, 462-475.	0.9	1,241
34	Systematic review of the oncological and functional outcomes of pelvic organâ€preserving radical cystectomy (<scp>RC</scp>) compared with standard <scp>RC</scp> in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU International, 2017, 120, 12-24.	1.3	63
35	Gleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score. Urologia Internationalis, 2017, 99, 156-161.	0.6	15
36	Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. BMC Cancer, 2016, 16, 483.	1.1	31

#	Article	IF	Citations
37	Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 106-115.	2.0	45
38	Value of positron emission tomography in diagnosing synchronous penile metastasis from urothelial bladder cancer. World Journal of Surgical Oncology, 2015, 13, 276.	0.8	9
39	Trends in Renal Function After Radical Cystectomy and Ileal Conduit Diversion: New Insights Regarding Estimated Glomerular Filtration Rate Variations. Clinical Genitourinary Cancer, 2015, 13, e139-e144.	0.9	18
40	Clinicopathological characteristics of urothelial bladder cancer in patients less than 40Âyears old. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 589-594.	1.4	125
41	Re: Long-Term Renal Function Outcomes after Radical Cystectomy. Journal of Urology, 2015, 193, 1066-1067.	0.2	0
42	Parotid gland metastasis from prostate cancer. Anti-Cancer Drugs, 2015, 26, 367-370.	0.7	2
43	Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer. Therapeutic Advances in Urology, 2015, 7, 125-134.	0.9	8
44	Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. European Journal of Surgical Oncology, 2014, 40, 1724-1730.	0.5	27
45	Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed nonâ€“muscle-invasive bladder cancer with positive results on urine cytology. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1135-1140.	0.8	25
46	Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: Ten years of follow-up. Scandinavian Journal of Urology, 2014, 48, 131-137.	0.6	19
47	Long-Term Women-Reported Quality of Life After Radical Cystectomy and Orthotopic Ileal Neobladder Reconstruction. Annals of Surgical Oncology, 2014, 21, 1398-1404.	0.7	32
48	1416 ARE WE EVALUATING PROPERLY THE RENAL FUNCTION WITH THE MODIFICATION OF DIET IN RENAL DISEASE (MDRD) IN PATIENTS WITH ORTHOTOPIC ILEAL NEOBLADDER?. Journal of Urology, 2013, 189, .	0.2	1
49	Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: A prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. European Journal of Cancer, 2013, 49, 431-438.	1.3	41
50	Inclusion of Patients With Advanced Cancer in Phase I Trials: Is This a Tool for Improving Optimism and Emotional Well-Being?. Journal of Clinical Oncology, 2013, 31, 817-818.	0.8	7
51	Management of Renal Cell Carcinoma in Sigmoid Kidney. Urologia Internationalis, 2012, 88, 483-485.	0.6	2
52	Re: Xiao-Dong Jin, Simone Roethlisberger, Fiona C. Burkhard, FrÃ©dÃ©ric Birkhaeuser, Harriet C. Thoeny, Urs E. Studer. Long-term Renal Function After Urinary Diversion by Ileal Conduit or Orthotopic Ileal Bladder Substitution. Eur Urol 2012;61:491â€“7. European Urology, 2012, 62, e55-e56.	0.9	1
53	Outcome of a Modified York Mason Technique in Men With Iatrogenic Urethrorectal Fistula After Radical Prostatectomy. Diseases of the Colon and Rectum, 2011, 54, 1008-1013.	0.7	24
54	Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2â€weighted, dynamic contrastâ€enhanced and diffusionâ€weighted imaging. BJU International, 2011, 107, 1411-1418.	1.3	278